Skip to main content
Premium Trial:

Request an Annual Quote

Inozyme, PreventionGenetics Partner to Offer Genetic Testing for Rare Calcification Disorders

NEW YORK (GenomeWeb) – Inozyme Pharma said today that it is instituting a no-cost genetic testing program in partnership with Wisconsin-based PreventionGenetics to improve the detection and understanding of two rare calcification disorders for which the drugmaker is developing treatments.

The program will offer free testing to eligible individuals with a suspect family history for mutations in the ENPP1 and ABCC6 genes, which are implicated in rare, severe calcification disorders, known as ENPP1 deficiency and ABCC6 deficiency, respectively.

The two companies are hoping that this may help individuals with these disorders be identified and diagnosed more quickly.

Inozyme CEO and co-founder Axel Bolte said in a statement that the effort will help to enhance the company's understanding of ENPP1 deficiency and ABCC6 deficiency, "with the ultimate goal of improving diagnosis and developing effective treatments."

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.